Message-ID: <4059253.1075855138864.JavaMail.evans@thyme> Date: Thu, 27 Dec 2001 09:11:20 -0800 (PST) From: skousen@investorplace.com To: don.baughman@enron.com Subject: Turn $1,000 into $20,000 Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-From: "Mark Skousen@InvestorPlace.com"<Insights2@reply.phillips.com>@ENRON X-To: Baughman Jr., Don </O=ENRON/OU=NA/CN=RECIPIENTS/CN=DBAUGHM> X-cc: X-bcc: X-Folder: \Edward_Baughman_Jan2002\Baughman Jr., Don\Inbox X-Origin: Baughman-E X-FileName: dbaughm (Non-Privileged).pst Dear Investor, This little biotech company just may have THE ANSWER to prostate cancer... ...and a lock on one of the largest -- and most lucrative -- health markets of the Western world. Best of all, its stock is what I call a "Why the heck not" investment. It's low-priced -- you can pick up a thousand shares for around $1,200 now. And it has the potential to MULTIPLY that small investment 10-to-20 TIMES over in the next couple years. See why I call it "Why the heck not?" Just a tiny amount of risk capital can turn into a really nice chunk of change. Frankly, my worst expectations are for a NEAR-TERM DOUBLE. That happens and you can even sell half your position, keep half -- and have none of your original investment at risk. Everything after that is gravy! THAT'S THE BIOTECH GAME, my friend. It's one of the few ways left for the average guy to get stinking rich. So if you've got a little cash to spare -- and have a love for tape-measure home runs -- you've got to check this stock out. Here's the story. Gene sequencing and human cloning get all the headlines, but a lot of the most compelling work in biotech comes from much more "boring" fields. This little company -- for example -- is doing AMAZING STUFF with common carbohydrate compounds. In fact, its experimental drug GBC-590 may prove to be one of the biggest success stories of the decade. LET ME STRESS the word "experimental." It's not approved yet -- it's still going through clinical trials. That's why the stock price is so low...but that's also why you have a chance to multiply your investment twenty fold -- if you get in now! This drug may be experimental, but it's also on the FAST-TRACK towards FDA-approval. Management stepped up the pace of clinical studies after initial results proved very favorable. In fact, Phase 1 results -- primarily used to show the safety of a drug -- showed REMARKABLE BENEFITS against prostate cancer. It stabilized or reduced PSA (prostate specific antigen) levels in 80% of the patients, with advanced cancer, tested! High PSAs, of course, are a marker of prostate cancer -- and a sign that the disease is spreading uncontrollably. Today, there is no effective treatment that improves the survival rates for men whose cancer continues to spread -- even after surgery. That's why this news is so important. It means new hope for patients who thought they had none. AND FOR INVESTORS like us, it means wealth potentially beyond our wildest dreams. Remember, clinical trials are still ongoing. But GBC- 590 seems to work by attaching itself to receptor points on individual cells, much like the space shuttle docks at the orbiting space station. Once "locked in," this drug thwarts the typical metastatic action -- that is, it stops the cancer from spreading! Imagine the wealth-building potential! But the story doesn't stop there. Animal-modeling with GBC-590 suggests a possible BREAKTHROUGH in the treatment of pancreatic cancer, which typically has a five-year death rate of 99%! 43% of mice survived past the 43-day benchmark versus none given the most-commonly used drug for pancreatic cancer. And 33% of the GBC-590 mice were 100% CURED of their tumors! Phase II trials on human pancreatic and colorectal cancer patients are now underway. And any positive news here should send this stock skyrocketing. WHAT'S MORE, this biotech is not some one-trick pony. One of its more interesting developments is CAN-296, a new breakthrough against drug-resistant fungus, including Aspergillus and Candida. Pre-clinical studies suggest it's very effective and extremely fast-acting. Icing on the cake! I won't claim that everyone should own this stock. It's an aggressive play, and no one should put a lot of money in it. But then again, you don't need a lot. Just a small investment now could well mushroom into a not-so-small FORTUNE over the next several years. I think it's worth a look -- and a few thousand dollars, as well. TRY A RISK-FREE trial subscription to my Forecasts & Strategies advisory and I'll give you this company's name NOW -- immediately, online. You'll also get a Special Introductory Report detailing all my top current recommendations. And trust me, they're not all biotech. I've got a host of stocks, funds, income vehicles and more that are all TOP-NOTCH investments for times like these. Best of all, when I say a "risk-free subscription," I mean it. Try Forecasts & Strategies for six full months and see if I'm blowing smoke or making you money. If you don't like F&S -- if you're not getting richer -- just say, "No thanks," and your subscription doesn't cost you a dime. That's an ironclad 6-month guarantee of total 100% satisfaction. So try Forecast & Strategies to see for yourself the advantages I bring. Go here now: http://www.ppi-orders.com/index.htm?promo_code=0YN139 Sincerely, Mark Skousen, Ph. D. Forecasts & Strategies P.S. I think this stock will make party chatter a lot of fun. Invest a thousand bucks and you could make enough to buy a new car. "Why the heck not?" Click here now: http://www.ppi-orders.com/index.htm?promo_code=0YN139 ------------------------------------------------------ ACCOUNT MANAGEMENT We hope this free digest of investing advice is valuable to you. If you'd like to change your e-mail address (DON.BAUGHMAN@ENRON.COM), or unsubscribe, please do so by going to the following address: http://www.investorplace.com/unsubscribe.php Your name will be removed from our list within 7-10 working days. ------------------------------------------------------ Thursday Dec 27, 2001 12:11:19